Peter B Cook, John H Hunt: Micronized aerosol steroids. Allen & Hanburys, Bacon & Thomas, November 8, 1983: US04414209 (156 worldwide citation)

An antiinflammatory steroid exhibiting a tendency to crystal growth in suspension in aerosol propellants is contacted with a halogenated hydrocarbon to form a crystalline solvate, which, after removal of some or all of the propellant from the crystals, is reduced to a particle size permitting inhala ...

Evan C Unger: Prodrugs comprising fluorinated amphiphiles. Imarx Pharmaceutical, Woodcock Washburn Kurtz Mackiewicz & Norris, February 22, 2000: US06028066 (125 worldwide citation)

The present invention describes, inter alia, novel prodrugs comprising fluorinated amphiphiles, compositions comprising the novel prodrugs, and methods of use of the prodrugs and compositions.

Mark F Pittenger: Adipogenic differentiation of human mesenchymal stem cells. Osiris Therapeutics, Charles J Herron, Elliot M Olstein, October 27, 1998: US05827740 (122 worldwide citation)

A composition which comprises human mesenchymal stem cells which have the potential to differentiate into cells of more than one connective tissue type and a composition which induces cells from the mesenchymal stem cell population to differentiate into the adipogenic lineage, and a process for indu ...

Chris A Buhr: Oligonucleotide having enhanced binding affinity. Gilead Sciences, January 23, 1996: US05486603 (119 worldwide citation)

The present invention relates to an oligonucleotide or analog thereof conjugated to a molecule comprising a structure, which structure (a) is of substantially fixed conformation; (b) contains, is directly attached to, or is attached to a carbon atom that is directly attached to, an first amine; and ...

Gary H Rasmusson, Glenn F Reynolds: 17.beta.-N-monosubstituted carbamoyl-4-aza-5.alpha.-androst-1-en-3-ones which are active as testosterone 5.alpha.-reductase inhibitors. Merck & Co, Charles M Caruso, Hesna J Pfeiffer, July 26, 1988: US04760071 (118 worldwide citation)

This invention is for the compound 17.beta.-(N-t-butylcarbamoyl)-4-aza-5.alpha.-androst-1-en-3-one, pharmaceutical compositions containing the compound, methods of inhibiting testosterone 5.alpha.-reductase with the compound and methods of treating hyperandrogenic conditions with the compound, parti ...

Takeshi Kinsho, Tsunehiro Nishi, Takeru Watanabe, Koji Hasegawa, Mutsuo Nakashima, Jun Hatakeyama: Acid-decomposable ester compound suitable for use in resist material. Shin-Etsu Chemical, Millen White Zelano & Branigan P C, September 10, 2002: US06448420 (106 worldwide citation)

A novel ester compound having an exo-form 2-alkylbicyclo[2.2.1]heptan-2-yl ester as the acid-decomposable site is used as a dissolution regulator to formulate a resist composition having a high sensitivity, resolution, etching resistance and storage stability.

Gordon H Phillipps, Brian M Bain, Ian P Steeples, Christopher Williamson: Androstane carbothioates. Glaxo Group, Bacon & Thomas, June 15, 1982: US04335121 (91 worldwide citation)

Compounds of the formula ##STR1## wherein R.sup.1 represents a fluoro-, chloro- or bromo-methyl group or a 2'-fluoroethyl group, R.sup.2 represents a group COR.sup.6 where R.sup.6 is a C.sub.1-3 alkyl group or OR.sup.2 and R.sup.3 together form a 16.alpha.,17.alpha.-isopropylidenedioxy group; R.sup. ...

Johnston David Bruce Randolph, Reinhold Donald Floyd, Rasmusson Gary Henry, Utne Torleif, Arth Glen Edward, Jobson Ronald Bradford: 4-aza-17-substituted-5-alpha-androstan-3-one, their a and d homo analogs, process for their preparation and pharmaceutical compositions containing them.. Merck & Co, October 31, 1979: EP0004949-A1 (88 worldwide citation)

4-Aza-17-substituted-5 alpha -androstan-3-ones and their A- and D- homo analogs of the formula: where Formula (I) may also have the structure of partial Formulas (II) and or (III); wherein, A is (1) - CH2 - CH2 -; (2) - CH = CH -; or B is (1) where R is, (a) hydrogen; (b) methyl or ethyl; (c) etheny ...

Lawrence John Penkler, Lu├ęta Ann De Kock, Darryl Vanstone Whittaker: Pharmaceutical composition containing acid addition salt of basic drug. Farmarc Nederland, Pillsbury Winthrop, July 3, 2001: US06255502 (86 worldwide citation)

A pharmaceutical composition contains an acid addition salt of a basic drug and a fatty acid or bile acid. The acid addition salts thus formed exhibit enhanced transmucosal and transdermal penetration of the basic drug. The acid addition salts, an inclusion complex containing said salts and a use of ...